Insilico Medicine begins clinical trial for AI-designed cancer drug ISM3412
Insilico medicine (“insilico”), a clinical-phase biotechnology company, which is operated by generative artificial intelligence (AI), today announces that the first patient with a global multi-layered clinical test (NCT064144460) with ISM3412 announces the first patient with a potential form, a potential form with a potential form. Tumor. The study of phase 1 includes two parts: increase […]